Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × pasireotide × Clear all

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Prostatic Neoplasms